Intrarenal dopamine modulates progressive angiotensin II-mediated renal injury

American Journal of Physiology - Renal Physiology

Volumn 302, Issue 6, 2012, Pages

  Yang, Shilin ^a   Yao, Bing ^a   Zhou, Yunfeng ^a   Yin, Huiyong ^a   Zhang, Ming Zhi ^a   Harris, Raymond C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Catechol O methyl transferase; Epidermal growth factor receptor; Glomerulosclerosis; Gludopa; Tubulointerstitial fibrosis

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ANGIOTENSIN II; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CALVASCULIN; CATECHOL METHYLTRANSFERASE; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; DOPAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; GAMMA GLUTAMYLDOPA; VASCULOTROPIN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE URINE LEVEL; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 84863229640     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00583.2011     Document Type: Article

References (40)

1. Aperia AC. Intrarenal dopamine: a key signal in the interactive regulation of sodium metabolism. Annu Rev Physiol 62: 621-647, 2000.
2. Armando I, Wang X, Villar VA, Jones JE, Asico LD, Escano C, Jose PA. Reactive oxygen species-dependent hypertension in dopamine D2 receptor-deficient mice. Hypertension 49: 672-678, 2007.
3. Berndt TJ, Liang M, Tyce GM, Knox FG. Intrarenal serotonin, dopamine, and phosphate handling in remnant kidneys. Kidney Int 59: 625-630, 2001.
4. Carey RM. Theodore Cooper Lecture: renal dopamine system: paracrine regulator of sodium homeostasis and blood pressure. Hypertension 38: 297-302, 2001.
5. Chen CJ, Apparsundaram S, Lokhandwala MF. Intrarenally produced angiotensin II opposes the natriuretic action of the dopamine-1 receptor agonist fenoldopam in rats. J Pharmacol Exp Ther 256: 486-491, 1991.
6. Chen JC, Chen JK, Nagai K, Plieth D, Tan M, Lee TC, Threadgill DW, Neilson EG, Harris RC. EGFR signaling promotes TGF-dependent renal fibrosis. JASN [Epub ahead of print].
7. Cheng H, Wang S, Jo YI, Hao CM, Zhang M, Fan X, Kennedy C, Breyer MD, Moeckel GW, Harris RC. Overexpression of cyclooxygenase-2 predisposes to podocyte injury. J Am Soc Nephrol 18: 551-559, 2007.
8. Cheng HF, Becker BN, Burns KD, Harris RC. Angiotensin II upregulates type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest 95: 2012-2019, 1995.
9. Cheng HF, Becker BN, Harris RC. Dopamine decreases expression of type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest 97: 2745-2752, 1996.
10. Choi MR, Lee BM, Medici C, Correa AH, Fernandez BE. Effects of angiotensin II on renal dopamine metabolism: synthesis, release, catabolism and turnover. Nephron Physiol 115: 1-7, 2010.
11. Choi MR, Medici C, Gironacci MM, Correa AH, Fernandez BE. Angiotensin II regulation of renal dopamine uptake and Na, K-ATPase activity. Nephron Physiol 111: 53-58, 2009.
12. De Luca Sarobe V, Nowicki S, Carranza A, Levin G, Barontini M, Arrizurieta E, Ibarra FR. Low sodium intake induces an increase in renal monoamine oxidase activity in the rat. Involvement of an angiotensin II dependent mechanism. Acta Physiol Scand 185: 161-167, 2005.
13. Eadington DW, Swainson CP, Frier BM, Johnston N, Samson RR, Lee MR. Urinary dopamine response to angiotensin II is not abnormal in type 1 (insulin-dependent) diabetes mellitus. Nephrol Dial Transplant 8: 36-40, 1993.
14. Eklof AC, Holtback U, Sundelof M, Chen S, Aperia A. Inhibition of COMT induces dopamine-dependent natriuresis and inhibition of proximal tubular Na, K-ATPase. Kidney Int 52: 742-747, 1997.
15. Gesek FA, Schoolwerth AC. Hormone responses of proximal Na-H exchanger in spontaneously hypertensive rats. Am J Physiol Renal Fluid Electrolyte Physiol 261: F526-F536, 1991.
16. Gildea JJ, Wang X, Jose PA, Felder RA. Differential D1 and D5 receptor regulation and degradation of the angiotensin type 1 receptor. Hypertension 51: 360-366, 2008.
17. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, Karayiorgou M. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 95: 9991-9996, 1998.
18. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94: 2504-2510, 1994.
19. Helkamaa T, Finckenberg P, Louhelainen M, Merasto S, Rauhala P, Lapatto R, Cheng ZJ, Reenila I, Mannisto P, Muller DN, Luft FC, Mervaala EM. Entacapone protects from angiotensin II-induced inflammation and renal injury. J Hypertens 21: 2353-2363, 2003.
20. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 11: 867-874, 2005.
21. Li H, Armando I, Yu P, Escano C, Mueller SC, Asico L, Pascua A, Lu Q, Wang X, Villar VA, Jones JE, Wang Z, Periasamy A, Lau YS, Soares-da-Silva P, Creswell K, Guillemette G, Sibley DR, Eisner G, Gildea JJ, Felder RA, Jose PA. Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. J Clin Invest 118: 2180-2189, 2008.
22. Miller PL, Rennke HG, Meyer TW. Glomerular hypertrophy accelerates hypertensive glomerular injury in rats. Am J Physiol Renal Fluid Electrolyte Physiol 261: F459-F465, 1991.
23. Narkar V, Kunduzova O, Hussain T, Cambon C, Parini A, Lokhandwala M. Dopamine D2-like receptor agonist bromocriptine protects against ischemia/reperfusion injury in rat kidney. Kidney Int 66: 633-640, 2004.
24. Salomone LJ, Howell NL, McGrath HE, Kemp BA, Keller SR, Gildea JJ, Felder RA, Carey RM. Intrarenal dopamine D1-like receptor stimulation induces natriuresis via an angiotensin type-2 receptor mechanism. Hypertension 49: 155-161, 2007.
25. Schnuelle P, Gottmann U, Hoeger S, Boesebeck D, Lauchart W, Weiss C, Fischereder M, Jauch KW, Heemann U, Zeier M, Hugo C, Pisarski P, Kramer BK, Lopau K, Rahmel A, Benck U, Birck R, Yard BA. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA 302: 1067-1075, 2009.
26. Singh AB, Sugimoto K, Harris RC. Juxtacrine activation of EGFR by membrane-anchored HB-EGF protects epithelial cells from anoikis while maintaining an epithelial phenotype. J Biol Chem 282: 32890-32901, 2007.
27. Wang X, Li F, Jose PA, Ecelbarger CM. Reduction of renal dopamine receptor expression in obese Zucker rats: role of sex and angiotensin II. Am J Physiol Renal Physiol 299: F1164-F1170, 2010.
28. Wang X, Villar VA, Armando I, Eisner GM, Felder RA, Jose PA. Dopamine, kidney, and hypertension: studies in dopamine receptor knockout mice. Pediatr Nephrol 23: 2131-2146, 2008.
29. Yang Z, Asico LD, Yu P, Wang Z, Jones JE, Escano CS, Wang X, Quinn MT, Sibley DR, Romero GG, Felder RA, Jose PA. D5 dopaminereceptor regulation of reactive oxygen species production, NADPH oxidase, and blood pressure. Am J Physiol Regul Integr Comp Physiol 290: R96-R104, 2006.
30. Yao B, Harris RC, Zhang MZ. Interactions between 11-hydroxysteroid dehydrogenase and COX-2 in kidney. Am J Physiol Regul Integr Comp Physiol 288: R1767-R1773, 2005.
31. Yasunari K, Kohno M, Kano H, Minami M, Yoshikawa J. Dopamine as a novel antioxidative agent for rat vascular smooth muscle cells through dopamine D(1)-like receptors. Circulation 101: 2302-2308, 2000.
32. Yatsu T, Aoki M, Inagaki O. Preventive effect of zelandopam, a dopamine D1 receptor agonist, on cisplatin-induced acute renal failure in rats. Eur J Pharmacol 461: 191-195, 2003.
33. Zelenina M, Zelenin S, Bondar AA, Brismar H, Aperia A. Water permeability of aquaporin-4 is decreased by protein kinase C and dopamine. Am J Physiol Renal Physiol 283: F309-F318, 2002.
34. Zeng C, Sanada H, Watanabe H, Eisner GM, Felder RA, Jose PA. Functional genomics of the dopaminergic system in hypertension. Physiol Genomics 19: 233-246, 2004.
35. Zeng C, Villar VA, Yu P, Zhou L, Jose PA. Reactive oxygen species and dopamine receptor function in essential hypertension. Clin Exp Hypertens 31: 156-178, 2009.
36. Zhang MZ, Wang JL, Cheng HF, Harris RC, McKanna JA. Cyclooxygenase-2 in rat nephron development. Am J Physiol Renal Physiol 273: F994-F1002, 1997.
37. Zhang MZ, Yao B, Cheng HF, Wang SW, Inagami T, Harris RC. Renal cortical cyclooxygenase 2 expression is differentially regulated by angiotensin II AT(1) and AT(2) receptors. Proc Natl Acad Sci USA 103: 16045-16050, 2006.
38. Zhang MZ, Yao B, Fang X, Wang S, Smith JP, Harris RC. Intrarenal dopaminergic system regulates renin expression. Hypertension 53: 564-570, 2009.
39. Zhang MZ, Yao B, McKanna JA, Harris RC. Cross talk between the intrarenal dopaminergic and cyclooxygenase-2 systems. Am J Physiol Renal Physiol 288: F840-F845, 2005.
40. Zhang MZ, Yao B, Wang S, Fan X, Wu G, Yang H, Yin H, Yang S, Harris RC. Intrarenal dopamine deficiency leads to hypertension and decreased longevity in mice. J Clin Invest 121: 2845-2854, 2011.